ORIC Pharmaceuticals provided program updates and announced upcoming key milestones. "In 2022, we made significant progress across our clinical pipeline, advanced multiple preclinical discovery programs, and further strengthened the balance sheet," said Jacob M. Chacko, MD, chief executive officer. "All three clinical programs commenced dosing last year, have demonstrated good oral bioavailability and dose proportional increases in exposure across multiple cohorts, and are steadily advancing in dose escalation without reaching MTD as we expand clinical trial sites globally. Furthermore, with the recent equity investment by Pfizer we have extended our cash runway into 2025, giving us flexibility to frontload Project Optimus-related dose optimization before selecting final RP2D for all three programs, and we expect to report initial clinical data for ORIC-533, ORIC-114, and ORIC-944 in the second half of 2023." ORIC anticipates the following upcoming milestones:ORIC-533: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with multiple myeloma in the second half of 2023. ORIC-114: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with EGFR/HER2-mutated cancers in the second half of 2023. ORIC-944: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with prostate cancer in the second half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORIC:
- ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Pfizer discloses 5.38M share stake in Oric Pharmaceuticals
- Oric Pharmaceuticals (NASDAQ:ORIC) Stock Spikes on Pfizer Deal
- Oric Pharmaceuticals to partner with Pfizer on ORIC-533, gets $25M investment
- ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer